Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

M. Kantarjian, Hagop; J. DeAngelo, Daniel; Stelljes, Matthias; Martinelli, Giovanni; Liedtke, Michaela; Stock, Wendy; Gökbuget, Nicola; O’Brien, Susan; Wang, Kongming; Wang, Tao; Luisa Paccagnella, M.; Sleight, Barbara; Vandendries, Erik; S. Advani, Anjali

doi:10.1056/nejmoa1509277

Public

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Published in New England Journal of Medicine • Jun 12, 2016

Authors:

Hagop M. Kantarjian

Daniel J. DeAngelo

Matthias Stelljes

Abstract

BACKGROUND: The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does ...

Subject

Calicheamicin

Medicine

Lymphoblastic Leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!